Skip to main content

Choice A or Choice B?

The inaugural post at the Personalized Medicine Coalition's new blog discusses the interplay of personalized medicine and comparative effectiveness. Amy Miller at The Age of Personalized Medicine writes that if "done right, CER could do more to advance personalized medicine than any other policy under consideration right now" but if "done wrong" could set the field back. She says that the US Congress has before it two comparative effectiveness bills, one of each flavor. Miller says the Senate Finance Committee's version incorporates personalized medicine into its comparative effectiveness proposal while the Senate HELP bill and H.R. 3200 give funds to conduct existing comparative effectiveness programs.

The Scan

Not Kept "Clean and Sanitary"

A Food and Drug Administration inspection uncovered problems with cross contamination at an Emergent BioSolutions facility, the Wall Street Journal reports.

Resumption Recommendation Expected

The Washington Post reports that US officials are expected to give the go-ahead to resume using Johnson & Johnson's SARS-CoV-2 vaccine.

Canada's New Budget on Science

Science writes that Canada's new budget includes funding for the life sciences, but not as much as hoped for investigator-driven research.

Nature Papers Examine Single-Cell, Multi-Omic SARS-CoV-2 Response; Flatfish Sequences; More

In Nature this week: single-cell, multi-omics analysis provides insight into COVID-19 pathogenesis, evolution of flatfish, and more.